Jiangsu (SH:688426)2026-02-27 08:35Financial Performance - The company achieved total operating revenue of 193.05 million yuan, a year-on-year increase of 53.36%[3] - The total profit for the period was -107.32 million yuan, and the net profit attributable to the parent company was -103.28 million yuan, both showing a reduction in losses compared to the previous year[5] - The basic earnings per share were -0.94 yuan, an improvement from -1.41 yuan in the previous year[3] Assets and Equity - The company's total assets at the end of the reporting period were 1,510.54 million yuan, a decrease of 6.65% from the beginning of the period[6] - The equity attributable to the parent company was 1,355.24 million yuan, down 7.54% from the beginning of the period[6] Business Growth and Strategy - The company focused on the rapid growth of technology service businesses such as gene sequencing and gene synthesis, which significantly contributed to revenue growth[7] - Operating efficiency improvements allowed the company to control expenses effectively, leading to a significant reduction in losses despite increased revenue[8] - Research and development expenses were optimized, resulting in a year-on-year decrease while focusing on advantageous projects[7] - The company emphasizes the importance of market-oriented resource allocation to enhance R&D efficiency[7] Financial Reporting - Investors are advised to note that the financial data presented are preliminary and unaudited, with final figures to be confirmed in the official annual report[9]